Tag: Diabetes Mellitus
Benefits of SGLT2 inhibitors may extend beyond HF-associated outcomes
High treatment success with ixekizumab in patients with psoriasis and diabetes

CHIEF-HF: Canagliflozin improves health status in heart failure

VOYAGER PAD: Fragile or diabetic patients also benefit from rivaroxaban
Antagonising the mineralocorticoid receptor beneficial for patients with diabetes and CKD
2021 ESC Guidelines on Heart Failure
2021 ESC Guidelines on Cardiovascular Disease Prevention
Novel mineralocorticoid receptor antagonist effective irrespective of HF history
Empagliflozin linked to lower cardiovascular risk and renal events in real-world study
Efficacy of dapagliflozin and empagliflozin not influenced by diabetes status
Biomarker panel predicts SGLT2 inhibitor response

JAK inhibitors and bDMARDs not associated with increased risk of serious infections in RA
Finerenone reduces the risk of AF onset in patients with CKD and diabetes

DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
Phase 3 BETonMACE trial did not meet its primary endpoint
